drugset / Trial / NCT06715462

Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy

NCT06715462

Phase 3 Withdrawn Eurofarma Laboratorios S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy (PDPN).

Timeline

Start
2026-04
Primary completion
2028-03
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg
Subject N0750 Unknown
Comparator Pregabalin Small molecule 150 mg